Shilpa announces the filing of ROTIGOTINE Transdermal System, USP, its FIRST TRANSDERMAL PATCH ANDA to the USFDA
SHILPAMED · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Shilpa Medicare has filed an Abbreviated New Drug Application (ANDA) for ROTIGOTINE Transdermal System, USP, with the US Food and Drug Administration (USFDA). This marks the company's first transdermal patch ANDA submission, expanding its presence in the US generic market. ROTIGOTINE is typically used in the treatment of Parkinson's disease and Restless Legs Syndrome. The transdermal patch is a new dosage form for Shilpa, signalling entry into a specialised drug delivery segment alongside its existing oral solids and injectables portfolio.
This is a positive development for shareholders as it diversifies Shilpa's product pipeline into the transdermal patch category, opening access to a niche US market with limited generic competition. Commercial revenue impact will depend on ANDA approval timing and market exclusivity, but the move strengthens the company's long-term growth narrative in regulated markets.